Heat Biologics Inc (NASDAQ:HTBX)’s share price traded up 3.2% during mid-day trading on Monday . The company traded as high as $0.40 and last traded at $0.39, 98,836 shares were traded during mid-day trading. A decline of 74% from the average session volume of 378,778 shares. The stock had previously closed at $0.37.
Separately, Brookline Capital Management assumed coverage on shares of Heat Biologics in a research report on Monday, July 29th. They issued a “buy” rating and a $8.00 price target on the stock.
The company has a market capitalization of $12.97 million, a P/E ratio of -0.43 and a beta of 1.76. The stock’s 50-day moving average price is $0.49 and its 200-day moving average price is $0.72. The company has a current ratio of 4.50, a quick ratio of 4.50 and a debt-to-equity ratio of 0.01.
Heat Biologics (NASDAQ:HTBX) last issued its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. The firm had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.91 million. Heat Biologics had a negative net margin of 386.16% and a negative return on equity of 75.51%. Sell-side analysts expect that Heat Biologics Inc will post -0.65 earnings per share for the current fiscal year.
An institutional investor recently raised its position in Heat Biologics stock. Vanguard Group Inc. boosted its position in Heat Biologics Inc (NASDAQ:HTBX) by 6.8% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,327,660 shares of the biopharmaceutical company’s stock after purchasing an additional 84,400 shares during the quarter. Vanguard Group Inc. owned about 3.90% of Heat Biologics worth $909,000 at the end of the most recent quarter. 5.55% of the stock is currently owned by institutional investors and hedge funds.
Heat Biologics Company Profile (NASDAQ:HTBX)
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Recommended Story: What is the outlook for the FAANG stocks?
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.